Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 3/20 | 0.41 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4788789 | 1.00 | TOP2A (0.41) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL9139881 | 1.00 | TOP2A (0.41) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL9846852 | 0.92 | ALDH1A1 (0.39) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL9846838 | 0.92 | ALDH1A1 (0.39) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL9139167 | 0.84 | TOP2A (0.41) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL9139155 | 0.84 | TOP2A (0.41) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL14529652 | 0.75 | OPRM1 (0.41) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL9250982 | 0.71 | MGAM (0.36) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL1101973 | 0.63 | — | — | |
| SCHEMBL7539678 | 0.62 | CRBN (0.42) | TOP2ATOP2BALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5438057-A | Administering a 1,2-bis(3,5-dioxo-4-piperazin-1-yl cyclobutane or-propane for cardioprotection particularly in conjunction with adriamycins | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1995-08-01 | — | — | US | claimed |
| EP-0548345-A1 | PHARMACEUTICAL COMPOSITIONS | BTG INTERNATIONAL LIMITED (GB) | 1993-06-30 | — | — | EP | claimed |
| WO-1993000901-A1 | PHARMACEUTICAL COMPOSITIONS | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1993-01-21 | — | — | WO | claimed |
| WO-2008134630-A1 | DEXRAZOXANE COMPOUNDS FOR CARDIOPROTECTION | APT PHARMACEUTICALS (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080275036-A1 | Prevention and treatment of cardiac conditions | APT PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| WO-2007053415-A2 | AGENTS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-5438057-A | Administering a 1,2-bis(3,5-dioxo-4-piperazin-1-yl cyclobutane or-propane for cardioprotection particularly in conjunction with adriamycins | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1995-08-01 | — | — | US | disclosed |
| EP-0548345-A1 | PHARMACEUTICAL COMPOSITIONS | BTG INTERNATIONAL LIMITED (GB) | 1993-06-30 | — | — | EP | disclosed |
| WO-1993000901-A1 | PHARMACEUTICAL COMPOSITIONS | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1993-01-21 | — | — | WO | disclosed |
| US-4275063-A | 1,2-BIS(3,5-DIOXOPIPERAZIN-YL)PROPANE FOR TREATMENT OF CANCER IN HUMANS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1981-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275036-A1 | Prevention and treatment of cardiac conditions | TNNT2, TNNI3, TNNC1 | TOP2A 1849/4885TOP2B 1324/4885ALDH1A1 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.